title: Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
authors.affiliation: Research Laboratories of Schering AG, Berlin (West) and Bergkamen, Federal Republic of Germany.
authors.forename: U F
authors.initials: UF
authors.lastname: Habenicht
authors.forename: H
authors.initials: H
authors.lastname: Schröder
authors.forename: M F
authors.initials: MF
authors.lastname: el Etreby
authors.forename: F
authors.initials: F
authors.lastname: Neumann
mesh_terms: D000726:Androgen Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017373:Cyproterone Acetate; D005260:Female; D005485:Flutamide / Q000627:therapeutic use; D005966:Glucuronidase / Q000378:metabolism; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006168:Guinea Pigs; D007668:Kidney / Q000201:enzymology; D008297:Male; D051379:Mice; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D012733:Sex Differentiation / Q000187:drug effects; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone; D017373:Cyproterone Acetate; D005485:Flutamide; D003534:Cyproterone; D005966:Glucuronidase; C030741:lutrelin acetate